Oramed Pharmaceuticals (NASDAQ:ORMP – Get Free Report) and Pluri (NASDAQ:PLUR – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership and analyst recommendations.
Earnings and Valuation
This table compares Oramed Pharmaceuticals and Pluri”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oramed Pharmaceuticals | $2.00 million | 99.42 | $64.05 million | $4.12 | 1.16 |
| Pluri | $1.34 million | 11.40 | -$22.58 million | ($4.53) | -0.30 |
Analyst Ratings
This is a summary of recent ratings and price targets for Oramed Pharmaceuticals and Pluri, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oramed Pharmaceuticals | 0 | 1 | 0 | 0 | 2.00 |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Oramed Pharmaceuticals and Pluri’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oramed Pharmaceuticals | N/A | -5.17% | -4.54% |
| Pluri | -2,162.08% | N/A | -106.59% |
Risk and Volatility
Oramed Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Pluri has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.
Institutional & Insider Ownership
12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
Oramed Pharmaceuticals beats Pluri on 9 of the 12 factors compared between the two stocks.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
About Pluri
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
